William Lay
Follow
Get notifications in MyBN when activity occurs.
William Lay
Group Chief Executive & Managing Director / Creso Pharma
William Lay is an experienced cannabis executive.
He was the executive vice president of strategy, origination & operations at Creso Pharma in September 2021 before becoming group chief executive and managing director in January 2022.
Mr Lay began his career with leading Canadian full-service financial investment bank BMO Capital Markets, through roles across Canada and London. He then joined TSE- and NASDAQ-listed Canopy Growth Corporation as an M&A associate before being promoted to M&A associate director where he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group.
For over four years, Mr Lay has managed and supported over C$5 billion in cannabis M&A transactions, including leading the largest acquisition in the history of the cannabis sector.
He was the executive vice president of strategy, origination & operations at Creso Pharma in September 2021 before becoming group chief executive and managing director in January 2022.
Mr Lay began his career with leading Canadian full-service financial investment bank BMO Capital Markets, through roles across Canada and London. He then joined TSE- and NASDAQ-listed Canopy Growth Corporation as an M&A associate before being promoted to M&A associate director where he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group.
For over four years, Mr Lay has managed and supported over C$5 billion in cannabis M&A transactions, including leading the largest acquisition in the history of the cannabis sector.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 815th | Creso Pharma | 1% | -27% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Creso Pharma | $144.7m |
200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
 | NEW ROLE: Group Chief Executive & Managing Director, Creso Pharma | 17 Jan 2022 |
